Aptar CSP Technologies has announced that its Activ-Film technology was selected for protecting a SARS rapid antigen test for Covid-19 developed by Quidel.
Quidel’s QuickVue SARS Antigen test is a point-of-care test, which provides results in ten minutes.
Last December, the US Food and Drug Administration (FDA) granted emergency use authorisation (EUA) to Quidel’s QuickVue SARS Antigen test for Covid-19 testing.
The visually read test does not require additional instrumentation and provides better access to affordable and accurate Covid-19 testing to meet urgent global testing needs.
Aptar CSP Technologies president and CEO Stephan Tanda said: “We are pleased to partner with Quidel Corporation on this critical diagnostic tool and help bring the QuickVue SARS Rapid Antigen test to the market.
“Our material science Activ-Film technology protects the test strips, helping to provide quick, reliable results.
“We will continue to live up to our purpose and responsibility to society by providing solutions that protect critical Covid-19 diagnostic kits, along with dispensing solutions
for medicines and consumer products needed by millions of people each day.”
The company’s Activ-Film technology is integrated into the kit to provide protection against moisture and other environmental conditions that can potentially affect the accuracy of the test.
Activ-Film uses Aptar’s 3-Phase Activ-Polymer technology, which offers a wide spectrum of custom-engineered protection in different configurations such as Activ-Vial for housing diagnostics dipsticks and Activ-Tab integrated within diagnostic cassettes.
Aptar CSP Technologies Commercial Operations vice-president Badre Hammond said: “As we continue to navigate through the Covid-19 crisis, this game-changing solution will help meet the urgent demand for Covid-19 testing in communities around the world.
“We are committed to leveraging our material science expertise to enable our partners to meet the ongoing need for innovative healthcare solutions that help improve and save lives.”